Prot#SL0012: A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability Of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/18/12 → 5/18/15

Funding

  • Parexel (SL0012 // SL0012)
  • UCB Biosciences, Inc. (SL0012 // SL0012)